ESCMID eAcademy

ePosters are only viewable by those with a valid ECCMID 2021 registration.
If you already have a registration, please login to the online platform here.
If you are not yet registered, you can do so here.
Abstract
Discussion Forum (0)
Abstract number: 1014

Session Type: ePosters

Session Title: ePosters

Authors(s): N. Paternotte, W. Rozemeijer, W. Boersma

Authors Affiliations(s): Northwest Clinics, Netherlands

Background:

Current diagnostic methods for pathogen detection in community-acquired pneumonia (CAP) are time-consuming and insensitive. Fast and accurate detection of pathogens can contribute to less inappropriate antibiotic prescription. The BioFire® FilmArray® Pneumonia Panel (PN-panel) (bioMérieux) is a rapid multiplex PCR detecting 26 respiratory pathogens (bacterial and viral). The aim of this study was to determine the added value of the FA-PP and the potential impact on antimicrobial treatment in patients with CAP.

Methods:

In a previous prospective study between 2014 and 2017 in a Dutch non-university teaching hospital, we collected sputum samples of hospitalized adult patients with CAP. Routine cultures were performed on these samples which were stored at -70°C afterwards. For the current study we randomly selected samples and tested those with the PN-panel. Based on demographic data, results of the PN-panel and results of routine microbiological tests, we determined for all CAP-cases a preferred antibiotic treatment. These antibiotic choices were compared to the actual treatment patients received.The primary outcome was the number of potential antimicrobial treatment changes.

Results:

57 sputum samples of CAP-patients were tested with the PN-panel. 39 (68.4%) patients were male, mean age was 68.8 years (standard deviation 16.1) and the majority of the patients had a CURB-65 score <2 (59.6%). In these 57 samples, 108 pathogens (32 viral, 76 bacterial) were detected with PN-panel and 55 with routine sputum cultures (table 1). Most frequent pathogens detected by PN-panel were Streptococcus pneumoniae, 25 (43.9%) and Haemophilus influenzae, 29 (50.9%) (table 2). If the results of the PN-panel would have been available in the first 24-hours of treatment, this would have potentially led to de-escalation of therapy in 19 (33.3%) and escalation in 8 (14.0%) patients. De-escalation would have led to a decrease of 109 days of broad-spectrum antibiotic treatment and escalation to an increase of 53 days. Change in therapy would have been inappropriate in 4 patients: 3 de-escalation, 1 escalation (table 3).

Conclusions:

PN-panel detected additional potential pathogens compared to routine sputum cultures. PN-panel has the potential to impact inappropriate antibiotic use in patients with CAP but consequences on patient outcomes need further studies.

Keyword(s): Community-acquired pneumonia, Diagnosis, BioFire Pneumonia Panel

Abstract number: 1014

Session Type: ePosters

Session Title: ePosters

Authors(s): N. Paternotte, W. Rozemeijer, W. Boersma

Authors Affiliations(s): Northwest Clinics, Netherlands

Background:

Current diagnostic methods for pathogen detection in community-acquired pneumonia (CAP) are time-consuming and insensitive. Fast and accurate detection of pathogens can contribute to less inappropriate antibiotic prescription. The BioFire® FilmArray® Pneumonia Panel (PN-panel) (bioMérieux) is a rapid multiplex PCR detecting 26 respiratory pathogens (bacterial and viral). The aim of this study was to determine the added value of the FA-PP and the potential impact on antimicrobial treatment in patients with CAP.

Methods:

In a previous prospective study between 2014 and 2017 in a Dutch non-university teaching hospital, we collected sputum samples of hospitalized adult patients with CAP. Routine cultures were performed on these samples which were stored at -70°C afterwards. For the current study we randomly selected samples and tested those with the PN-panel. Based on demographic data, results of the PN-panel and results of routine microbiological tests, we determined for all CAP-cases a preferred antibiotic treatment. These antibiotic choices were compared to the actual treatment patients received.The primary outcome was the number of potential antimicrobial treatment changes.

Results:

57 sputum samples of CAP-patients were tested with the PN-panel. 39 (68.4%) patients were male, mean age was 68.8 years (standard deviation 16.1) and the majority of the patients had a CURB-65 score <2 (59.6%). In these 57 samples, 108 pathogens (32 viral, 76 bacterial) were detected with PN-panel and 55 with routine sputum cultures (table 1). Most frequent pathogens detected by PN-panel were Streptococcus pneumoniae, 25 (43.9%) and Haemophilus influenzae, 29 (50.9%) (table 2). If the results of the PN-panel would have been available in the first 24-hours of treatment, this would have potentially led to de-escalation of therapy in 19 (33.3%) and escalation in 8 (14.0%) patients. De-escalation would have led to a decrease of 109 days of broad-spectrum antibiotic treatment and escalation to an increase of 53 days. Change in therapy would have been inappropriate in 4 patients: 3 de-escalation, 1 escalation (table 3).

Conclusions:

PN-panel detected additional potential pathogens compared to routine sputum cultures. PN-panel has the potential to impact inappropriate antibiotic use in patients with CAP but consequences on patient outcomes need further studies.

Keyword(s): Community-acquired pneumonia, Diagnosis, BioFire Pneumonia Panel

Effect of the FilmArray® Pneumonia Panel on antimicrobial treatment in community-acquired pneumonia
Ms. Nienke Paternotte
Ms. Nienke Paternotte
ESCMID eAcademy. Paternotte N. 07/09/2021; 327917; 1014;
user
Ms. Nienke Paternotte
Abstract
Discussion Forum (0)
Abstract number: 1014

Session Type: ePosters

Session Title: ePosters

Authors(s): N. Paternotte, W. Rozemeijer, W. Boersma

Authors Affiliations(s): Northwest Clinics, Netherlands

Background:

Current diagnostic methods for pathogen detection in community-acquired pneumonia (CAP) are time-consuming and insensitive. Fast and accurate detection of pathogens can contribute to less inappropriate antibiotic prescription. The BioFire® FilmArray® Pneumonia Panel (PN-panel) (bioMérieux) is a rapid multiplex PCR detecting 26 respiratory pathogens (bacterial and viral). The aim of this study was to determine the added value of the FA-PP and the potential impact on antimicrobial treatment in patients with CAP.

Methods:

In a previous prospective study between 2014 and 2017 in a Dutch non-university teaching hospital, we collected sputum samples of hospitalized adult patients with CAP. Routine cultures were performed on these samples which were stored at -70°C afterwards. For the current study we randomly selected samples and tested those with the PN-panel. Based on demographic data, results of the PN-panel and results of routine microbiological tests, we determined for all CAP-cases a preferred antibiotic treatment. These antibiotic choices were compared to the actual treatment patients received.The primary outcome was the number of potential antimicrobial treatment changes.

Results:

57 sputum samples of CAP-patients were tested with the PN-panel. 39 (68.4%) patients were male, mean age was 68.8 years (standard deviation 16.1) and the majority of the patients had a CURB-65 score <2 (59.6%). In these 57 samples, 108 pathogens (32 viral, 76 bacterial) were detected with PN-panel and 55 with routine sputum cultures (table 1). Most frequent pathogens detected by PN-panel were Streptococcus pneumoniae, 25 (43.9%) and Haemophilus influenzae, 29 (50.9%) (table 2). If the results of the PN-panel would have been available in the first 24-hours of treatment, this would have potentially led to de-escalation of therapy in 19 (33.3%) and escalation in 8 (14.0%) patients. De-escalation would have led to a decrease of 109 days of broad-spectrum antibiotic treatment and escalation to an increase of 53 days. Change in therapy would have been inappropriate in 4 patients: 3 de-escalation, 1 escalation (table 3).

Conclusions:

PN-panel detected additional potential pathogens compared to routine sputum cultures. PN-panel has the potential to impact inappropriate antibiotic use in patients with CAP but consequences on patient outcomes need further studies.

Keyword(s): Community-acquired pneumonia, Diagnosis, BioFire Pneumonia Panel

Abstract number: 1014

Session Type: ePosters

Session Title: ePosters

Authors(s): N. Paternotte, W. Rozemeijer, W. Boersma

Authors Affiliations(s): Northwest Clinics, Netherlands

Background:

Current diagnostic methods for pathogen detection in community-acquired pneumonia (CAP) are time-consuming and insensitive. Fast and accurate detection of pathogens can contribute to less inappropriate antibiotic prescription. The BioFire® FilmArray® Pneumonia Panel (PN-panel) (bioMérieux) is a rapid multiplex PCR detecting 26 respiratory pathogens (bacterial and viral). The aim of this study was to determine the added value of the FA-PP and the potential impact on antimicrobial treatment in patients with CAP.

Methods:

In a previous prospective study between 2014 and 2017 in a Dutch non-university teaching hospital, we collected sputum samples of hospitalized adult patients with CAP. Routine cultures were performed on these samples which were stored at -70°C afterwards. For the current study we randomly selected samples and tested those with the PN-panel. Based on demographic data, results of the PN-panel and results of routine microbiological tests, we determined for all CAP-cases a preferred antibiotic treatment. These antibiotic choices were compared to the actual treatment patients received.The primary outcome was the number of potential antimicrobial treatment changes.

Results:

57 sputum samples of CAP-patients were tested with the PN-panel. 39 (68.4%) patients were male, mean age was 68.8 years (standard deviation 16.1) and the majority of the patients had a CURB-65 score <2 (59.6%). In these 57 samples, 108 pathogens (32 viral, 76 bacterial) were detected with PN-panel and 55 with routine sputum cultures (table 1). Most frequent pathogens detected by PN-panel were Streptococcus pneumoniae, 25 (43.9%) and Haemophilus influenzae, 29 (50.9%) (table 2). If the results of the PN-panel would have been available in the first 24-hours of treatment, this would have potentially led to de-escalation of therapy in 19 (33.3%) and escalation in 8 (14.0%) patients. De-escalation would have led to a decrease of 109 days of broad-spectrum antibiotic treatment and escalation to an increase of 53 days. Change in therapy would have been inappropriate in 4 patients: 3 de-escalation, 1 escalation (table 3).

Conclusions:

PN-panel detected additional potential pathogens compared to routine sputum cultures. PN-panel has the potential to impact inappropriate antibiotic use in patients with CAP but consequences on patient outcomes need further studies.

Keyword(s): Community-acquired pneumonia, Diagnosis, BioFire Pneumonia Panel

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies